A growing library of the omega-3 research we're following — summarized and categorized so you can find what matters to you.
High-dose (≥1,200 mg/day) early-life omega-3 supplementation was linked to a lower risk of childhood asthma/wheezing, with each extra 1,000 mg/day associated with about a 26% risk reduction.
Omega-3 supplementation significantly raised blood levels of two precursor compounds linked to the body's natural inflammation-resolving pathways, especially in people with existing inflammatory or metabolic conditions.
In a study of nearly half a million people, traditional risk factors like age and genetics were more strongly linked to atrial fibrillation than blood fatty acid levels, though higher omega-6 levels were associated with lower AFib rates.
Teens taking a daily algae-derived omega-3 blend for 16 weeks showed better word recall and faster attention task reaction times than those on placebo.
93% of elite Australian athletes had blood omega-3 levels below the 8% threshold linked to lower cardiovascular risk, with intake averaging only about 261 mg of DHA+EPA per day.
In a 12-week trial, high-dose krill oil extract was linked to reduced arterial stiffness and changes in platelet-related markers compared to placebo in healthy adults.
A six-factor risk score (age, sex, BMI, heart failure, insulin-treated diabetes, and inflammation marker levels) moderately predicted new atrial fibrillation in patients taking a concentrated omega-3 supplement in the STRENGTH trial.
A review of 23 randomized trials found anthocyanins, omega-3s, and several other plant compounds were most consistently linked to improved activity of PON1, an enzyme that supports HDL's protective functions.
In a large population study, certain fat-derived molecules, including omega-3 fatty acids like EPA, were associated with different patterns of lung function, though this does not prove cause and effect.